Patents by Inventor Holger Luebben

Holger Luebben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10329536
    Abstract: The present invention concerns a method for production of an active ingredient of a drug or diagnostic agent, in which (a) MDCK cells are infected with a virus; and (b) the MDCK cells are cultured in suspension culture on a commercial scale under conditions that permit multiplication of the viruses; in which culturing occurs in a volume of at least 30 L. The invention also concerns a method for production of a drug or diagnostic agent in which an active ingredient is produced according to the above method and mixed with an appropriate adjuvant, auxiliary, buffer, diluent or drug carrier.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 25, 2019
    Assignee: Seqirus UK Limited
    Inventors: Jürgen Vorlop, Christian Frech, Holger Lübben, Jens-Peter Gregersen
  • Publication number: 20190142927
    Abstract: An influenza vaccine lacks at least three of: a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components.
    Type: Application
    Filed: June 26, 2018
    Publication date: May 16, 2019
    Inventors: Jens-Peter GREGERSEN, Holger Luebben, Juergen Vorlop
  • Publication number: 20170119871
    Abstract: An influenza vaccine lacks at least three of: a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components.
    Type: Application
    Filed: June 24, 2016
    Publication date: May 4, 2017
    Inventors: Jens-Peter Gregersen, Holger Luebben, Juergen Vorlop
  • Publication number: 20100183671
    Abstract: An influenza vaccine that lacks at least three of a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components.
    Type: Application
    Filed: June 27, 2008
    Publication date: July 22, 2010
    Applicant: Novartis Vaccines & Diagnostics GmbH & Co., KG
    Inventors: Jens-Peter Gregersen, Holger Luebben, Juergen Vorlop